Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has been effective vigilantly but unsuccessfully to create an one-time therapy, variously called Pro 140, leronlimab, along with Vyrologix.

In development of this treatment, CytoDyn has cast its net wide and far both geographically and in terms of prospective indications.

CytoDyn’s inventories of leronlimab are building up, whether they’ll actually be used is actually an open question.

While CYDY  happens to be dawdling, market opportunities for leronlimab as a combination therapy in the therapy of multi-drug-resistant HIV happen to be closing.

I am composing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale made of my past several shares. The 1st CytoDyn post of mine, “CytoDyn: What to be able to Do When It’s Too Good In order to Be True?”, set away all of the following prediction:

Rather I expect it to turn into a serial disappointer. CEO Pourhassan presented such a highly promotional image in the Uptick Newswire interview that I came away with a bad impression of the company.

Irony of irony, my bad opinion of the business enterprise has grown steadily, however, the disappointment has not been financial. Two years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > 6 bagger yet still disappoints? Therein is the story; allow me to explain.

CytoDyn acquired its much storied therapy (which I shall relate to as leronlimab) back during 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for the therapy as well as avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti-viral activity in HIV- infected subjects. Today’s transaction of $3.5 zillion transfers ownership of this technology as well as associated intellectual property coming from Progenics to CytoDyn, as well as approximately twenty five million mg of bulk drug substance…. milestone payments after commencement of a phase III clinical trial ($1.5 million) as well as the first brand new drug application endorsement ($five million), and also royalty payments of 5 % of net sales upon commercialization.

Since that point in time, CytoDyn’s guiding nous, Nader Pourhassan [NP] has turned this inauspicious acquisition right into a springboard for CytoDyn to purchase a market place cap > $3.5 billion. It’s done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with numerous therapies and many indications, it’s this individual remedy in addition to a “broad pipeline of indications” because it places it. I call some pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a potentially advantageous therapy of dozens of indications.

Its opening banner on its site (below) shows an energetic business with diverse interests albeit centered on leronlimab, several illness sorts, multiple publications in addition to multiple presentations.

Can it all be smoke cigarettes and mirrors? That’s a question I have been asking myself from the really start of the interest of mine in this particular company. Judging by way of the multiples of a huge number of diverse commentary on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I’m far from alone in this question.

CytoDyn is a classic battleground, or maybe some could say cult stock. Its adherents are fiercely protective of the prospects of its, quick to label some bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *